Shilpa Medicare’s OERIS™ Achieves Positive Phase III Results for Chemotherapy-Induced Nausea Shilpa Medicare has announced positive Phase III results for its OERIS™ injection, effectively treating chemotherapy-induced nausea and vomiting, enhancing patient care.

Shilpa Medicare’s OERIS™ Achieves Positive Phase III Results for Chemotherapy-Induced Nausea #India #Shilpa_Medicare #Raichur #OERIS™ #CINV

Shilpa Pharma Lifesciences Achieves Gold Medal for Sustainability Excellence Shilpa Pharma Lifesciences Limited proudly announces its recognition with the Gold Medal from EcoVadis for outstanding sustainability practices in business operations.

Shilpa Pharma Lifesciences Achieves Gold Medal for Sustainability Excellence #India #Sustainability_Practices #Shilpa_Medicare #Raichur #EcoVadis_Medal

Shilpa Medicare Achieves Positive Phase 3 Study Results for OERIS™, Transforming Chemotherapy Nausea Care Shilpa Medicare has successfully completed a Phase 3 study for OERIS™, showing enhanced efficacy and safety for chemotherapy-induced nausea and vomiting. This innovative injection can significantly improve patient care.

Shilpa Medicare Achieves Positive Phase 3 Study Results for OERIS™, Transforming Chemotherapy Nausea Care #India #Shilpa_Medicare #Raichur #OERIS™ #CINV

Shilpa Medicare's OERIS™ Achieves Positive Results in Phase 3 Trials for Chemotherapy-Induced Nausea Shilpa Medicare has announced positive results from Phase 3 trials for OERIS™, a novel ondansetron injection aimed at treating chemotherapy-induced nausea. The study highlights its efficacy and safety.

Shilpa Medicare's OERIS™ Achieves Positive Results in Phase 3 Trials for Chemotherapy-Induced Nausea #India #Shilpa_Medicare #Raichur #OERIS™ #CINV

Shilpa Medicare Reports Positive Phase 3 Results for OERIS™: A NewWeekly Ondansetron Injection for Chemotherapy-Induced Nausea Shilpa Medicare's OERIS™ has successfully completed Phase 3 trials, showcasing superior convenience and efficacy for chemotherapy-induced nausea. This innovation enhances patient care by reducing treatment frequency.

Shilpa Medicare Reports Positive Phase 3 Results for OERIS™: A NewWeekly Ondansetron Injection for Chemotherapy-Induced Nausea #India #Chemotherapy #Shilpa_Medicare #Raichur #OERIS™

Shilpa Medicare's NorUDCA Gains Notable Approval as First Global NAFLD Therapy Shilpa Medicare's NorUDCA is the world's first approved therapy for Non-Alcoholic Fatty Liver Disease, offering hope to millions affected globally.

Shilpa Medicare's NorUDCA Gains Notable Approval as First Global NAFLD Therapy #India #Shilpa_Medicare #Raichur #NorUDCA #NAFLD

Shilpa Medicare's NorUDCA Achieves Milestone as First Approved NAFLD Therapy Shilpa Medicare has made history with NorUDCA, the world's first approved therapy for NAFLD, offering hope for over 1 billion patients globally.

Shilpa Medicare's NorUDCA Achieves Milestone as First Approved NAFLD Therapy #India #Shilpa_Medicare #Raichur #NorUDCA #NAFLD

Shilpa Medicare's NorUDCA Marks a Revolutionary Approval for NAFLD Treatment Shilpa Medicare's groundbreaking therapy NorUDCA is the first globally approved treatment for NAFLD, promising hope for over a billion affected individuals.

Shilpa Medicare's NorUDCA Marks a Revolutionary Approval for NAFLD Treatment #India #Shilpa_Medicare #Raichur #NorUDCA #NAFLD

Shilpa Medicare Makes Groundbreaking Move with NorUDCA, First NAFLD Therapy Approved Worldwide Shilpa Medicare's NorUDCA is the first-ever therapy approved globally for Non-Alcoholic Fatty Liver Disease, offering hope to millions suffering worldwide.

Shilpa Medicare Makes Groundbreaking Move with NorUDCA, First NAFLD Therapy Approved Worldwide #India #Shilpa_Medicare #Raichur #NorUDCA #NAFLD

Alveolus Bio Partners with Shilpa Medicare to Revolutionize Lung Disease Treatments Alveolus Bio has received strategic investment from Shilpa Medicare, setting the stage for groundbreaking treatments in respiratory health.

Alveolus Bio Partners with Shilpa Medicare to Revolutionize Lung Disease Treatments #USA #Birmingham #Shilpa_Medicare #Alveolus_Bio #pulmonary_therapies

Alveolus Bio's Strategic Investment with Shilpa Medicare Enhances Pulmonary Therapeutics Development Alveolus Bio has secured a significant investment from Shilpa Medicare to advance innovative therapies for respiratory diseases, gearing up for essential clinical trials.

Alveolus Bio's Strategic Investment with Shilpa Medicare Enhances Pulmonary Therapeutics Development #United_States #Birmingham #COPD #Shilpa_Medicare #Alveolus_Bio

Alveolus Bio Receives Investment to Propel Innovative Pulmonary Therapies Alveolus Bio, led by Dr. Vivek Lal, has gained a strategic investment from Shilpa Medicare, advancing its groundbreaking respiratory treatments.

Alveolus Bio Receives Investment to Propel Innovative Pulmonary Therapies #USA #Birmingham #Shilpa_Medicare #Alveolus_Bio #pulmonary_therapies

Alveolus Bio Secures Strategic Investment from Shilpa Medicare for Revolutionary Lung Therapies Alveolus Bio recently received a strategic investment from Shilpa Medicare, setting the stage for breakthrough lung disease treatments.

Alveolus Bio Secures Strategic Investment from Shilpa Medicare for Revolutionary Lung Therapies #USA #Birmingham #Shilpa_Medicare #Alveolus_Bio #Lung_Therapy

Alveolus Bio Secures Strategic Investment from Shilpa Medicare for Revolutionary Pulmonary Therapies Alveolus Bio has secured a pivotal investment from Shilpa Medicare, enhancing its capabilities in advancing cutting-edge therapies for respiratory diseases.

Alveolus Bio Secures Strategic Investment from Shilpa Medicare for Revolutionary Pulmonary Therapies #USA #Birmingham #Shilpa_Medicare #Alveolus_Bio #respiratory_therapies

Shilpa Medicare Wins SEC-CDSCO Approval for Nor-Ursodeoxycholic Acid Tablets Against NASH Shilpa Medicare has obtained regulatory approval for Nor-Ursodeoxycholic Acid tablets, a promising treatment for non-alcoholic fatty liver disease, paving the way for an upcoming market launch.

Shilpa Medicare Wins SEC-CDSCO Approval for Nor-Ursodeoxycholic Acid Tablets Against NASH #India #NASH #Shilpa_Medicare #Raichur #Nor_UDCA

Shilpa Medicare Introduces Nor-Ursodeoxycholic Acid for NASH Treatment Shilpa Medicare recently gained approval for Nor-Ursodeoxycholic Acid tablets, aiming to tackle non-alcoholic steatohepatitis with a market launch planned in India.

Shilpa Medicare Introduces Nor-Ursodeoxycholic Acid for NASH Treatment #India #NASH #Shilpa_Medicare #Raichur #Nor_UDCA

Shilpa Medicare Receives SEC Approval for Nor-UDCA Tablets Targeting NASH Treatment Market Shilpa Medicare has obtained SEC clearance for Nor-UDCA tablets aimed at treating non-alcoholic steatohepatitis (NASH), a growing global health concern.

Shilpa Medicare Receives SEC Approval for Nor-UDCA Tablets Targeting NASH Treatment Market #India #NASH #Shilpa_Medicare #Nor-UDCA #Raichur